Skip to main content
Caplight Logo









Pluri is now publicly traded

The data on this page reflects Pluri's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Private Placement

Feb 4, 2025

Total Funding Raised

$248.68M

Company Overview

Pluri Inc. is a biotechnology company that develops cell-based products for a variety of industries, including regenerative medicine, food technology, and agriculture technology.

AI Layer

Non-AI

Keywords

CDMOcontract development and manufacturing organizationcell therapy3D cell expansioncell manufacturingregenerative medicinecultivated meatlab-grown meatcellular agriculturebiomanufacturingcell therapy manufacturingplacenta-based cell therapyGMP manufacturingbioreactor systemregenerative aestheticscell-based coffee

Pluri Comparables

Compare Pluri with similar companies based on industry and business-model similarity.

No public comparables are available for Pluri. Request access to learn about comparables coverage.

Request access

Pluri Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private PlacementFeb 4, 2025
Private PlacementJan 23, 2025
GrantNov 10, 2021
DebtMay 25, 2021
Follow-on OfferingFeb 2, 2021
Follow-on Offering
May 5, 2020

Key People

Founding team and executive leadership

Yaky Yanay

CEO President

Executive Team

Liat Zalts

Chief Financial Officer

Executive Team

Lior Raviv

Chief Technology Officer, Vice President Development Operations

Executive Team

Pluri Investors

Notable investors and investment history

Pluri Filings

Explore SEC and related filing metadata, where available.

Pluri filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

Headquarters—
Employee Range253
Year Founded2001
Last FundingFeb 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?